Ovarian cancer, version 3.2012.

These NCCN Guidelines Insights focus on the major updates for the 2012 NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Ovarian Cancer by describing how and why the new recommendations were made. The 6 update topics were selected based on recent important updates in the guidelines and on debate among panel members about recent clinical trials, and include: 1) screening, 2) diagnostic tests for assessing pelvic masses, 3) primary treatment using neoadjuvant chemotherapy, 4) primary adjuvant treatment using bevacizumab in combination with chemotherapy, 5) therapy for recurrent disease, and 6) management of drug/hypersensitivity reactions. These NCCN Guidelines Insights also discuss why some recommendations were not made (eg, panel members did not feel the new data warranted changing the guideline). See "Updates" in the NCCN Guidelines for Ovarian Cancer for a complete list of all the recent revisions.

[1]  D. Matei,et al.  Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. , 2012, The New England journal of medicine.

[2]  O. Brawley,et al.  Cancer screening in the United States, 2012 , 2012, CA: a cancer journal for clinicians.

[3]  J. Sampalis,et al.  Assessment of symptomatic women for early diagnosis of ovarian cancer: results from the prospective DOvE pilot project. , 2012, The Lancet. Oncology.

[4]  Y. Yen,et al.  Ovarian Cancer: Opportunity for Targeted Therapy , 2011, Journal of oncology.

[5]  J. Yi,et al.  OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  D. Levine,et al.  An analysis of patients with bulky advanced stage ovarian, tubal, and peritoneal carcinoma treated with primary debulking surgery (PDS) during an identical time period as the randomized EORTC-NCIC trial of PDS vs neoadjuvant chemotherapy (NACT). , 2012, Gynecologic oncology.

[7]  A. Jemal,et al.  Cancer statistics, 2012 , 2012, CA: a cancer journal for clinicians.

[8]  B. Monk,et al.  Incorporation of bevacizumab in the primary treatment of ovarian cancer. , 2011, The New England journal of medicine.

[9]  Jacobus Pfisterer,et al.  A phase 3 trial of bevacizumab in ovarian cancer. , 2011, The New England journal of medicine.

[10]  I. Vergote,et al.  Neoadjuvant chemotherapy is the better treatment option in some patients with stage IIIc to IV ovarian cancer. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  R. Molina,et al.  HE4 a novel tumour marker for ovarian cancer: comparison with CA 125 and ROMA algorithm in patients with gynaecological diseases , 2011, Tumor Biology.

[12]  A. Bryant,et al.  Optimal primary surgical treatment for advanced epithelial ovarian cancer. , 2011, The Cochrane database of systematic reviews.

[13]  M. Markman.  Pegylated liposomal doxorubicin: appraisal of its current role in the management of epithelial ovarian cancer , 2011, Cancer management and research.

[14]  J. Gohagan,et al.  Effect of screening on ovarian cancer mortality: the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Randomized Controlled Trial. , 2011, JAMA.

[15]  D. Goldstein,et al.  No benefit from combining HE4 and CA125 as ovarian tumor markers in a clinical setting. , 2011, Gynecologic oncology.

[16]  D. Smith,et al.  Activity of cabozantinib (XL184) in advanced ovarian cancer patients (pts): Results from a phase II randomized discontinuation trial (RDT). , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  D. Cohn,et al.  At what cost does a potential survival advantage of bevacizumab make sense for the primary treatment of ovarian cancer? A cost-effectiveness analysis. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  M. Hensley.  Big costs for little gain in ovarian cancer. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  Giuseppe Lippi,et al.  The ROMA (Risk of Ovarian Malignancy Algorithm) for estimating the risk of epithelial ovarian cancer in women presenting with pelvic mass: is it really useful? , 2011, Clinical chemistry and laboratory medicine.

[20]  A. Romano,et al.  Diagnosis and management of drug hypersensitivity reactions. , 2011, The Journal of allergy and clinical immunology.

[21]  J. Schorge,et al.  Primary Debulking Surgery Versus Neoadjuvant Chemotherapy in Stage IV Ovarian Cancer , 2012, Annals of Surgical Oncology.

[22]  Sudhir Srivastava,et al.  Ovarian Cancer Biomarker Performance in Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial Specimens , 2011, Cancer Prevention Research.

[23]  D Timmerman,et al.  HE4 and CA125 as a diagnostic test in ovarian cancer: prospective validation of the Risk of Ovarian Malignancy Algorithm , 2011, British Journal of Cancer.

[24]  A. Vlad,et al.  Cancer Management and Research Dovepress Targeted Treatment of Recurrent Platinum-resistant Ovarian Cancer: Current and Emerging Therapies , 2022 .

[25]  G. Jayson,et al.  Outcomes After Multiple Lines of Chemotherapy for Platinum-Resistant Epithelial Cancers of the Ovary, Peritoneum, and Fallopian Tube , 2010, International Journal of Gynecologic Cancer.

[26]  P. Demoly,et al.  General considerations on rapid desensitization for drug hypersensitivity – a consensus statement , 2010, Allergy.

[27]  B. Rimel,et al.  The role of neoadjuvant chemotherapy in the management of patients with advanced stage ovarian cancer: survey results from members of the Society of Gynecologic Oncologists. , 2010, Gynecologic oncology.

[28]  G. Kenter,et al.  Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. , 2010, The New England journal of medicine.

[29]  R. Bast,et al.  Serum biomarker panels for the discrimination of benign from malignant cases in patients with an adnexal mass. , 2010, Gynecologic oncology.

[30]  Gary Goodman,et al.  Assessing Lead Time of Selected Ovarian Cancer Biomarkers: A Nested Case–Control Study , 2010, Journal of the National Cancer Institute.

[31]  D. Clarke‐Pearson,et al.  Clinical practice. Screening for ovarian cancer. , 2009, The New England journal of medicine.

[32]  D. Levine,et al.  Improved progression-free and overall survival in advanced ovarian cancer as a result of a change in surgical paradigm. , 2009, Gynecologic oncology.

[33]  Matthew Burnell,et al.  Sensitivity and specificity of multimodal and ultrasound screening for ovarian cancer, and stage distribution of detected cancers: results of the prevalence screen of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS) , 2009, Journal of Family Planning and Reproductive Health Care.

[34]  L. Stead,et al.  Visual representation of National Institute of Allergy and Infectious Disease and Food Allergy and Anaphylaxis Network criteria for anaphylaxis , 2009, International journal of emergency medicine.

[35]  P. Colombo,et al.  Aggressive surgical strategies in advanced ovarian cancer: a monocentric study of 203 stage IIIC and IV patients. , 2009, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[36]  N. Spirtos,et al.  Gynecologic Oncology Group Surgical Procedures Manual , 2009 .

[37]  U. Matulonis,et al.  Food , drug , insect sting allergy , and anaphylaxis Hypersensitivity reactions to chemotherapy : Outcomes and safety of rapid desensitization in 413 cases , 2022 .

[38]  Michael W Sill,et al.  Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[39]  Howard Mackey,et al.  Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[40]  A. Fader,et al.  Role of surgery in ovarian carcinoma. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[41]  D. Mutch,et al.  Randomized phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[42]  H. Lenz.  Management and preparedness for infusion and hypersensitivity reactions. , 2007, The oncologist.

[43]  Jubilee Brown,et al.  Evaluation of the incidence of carboplatin hypersensitivity reactions in cancer patients. , 2006, Gynecologic oncology.

[44]  D. Hepner,et al.  Second symposium on the definition and management of anaphylaxis: summary report--Second National Institute of Allergy and Infectious Disease/Food Allergy and Anaphylaxis Network symposium. , 2006, The Journal of allergy and clinical immunology.

[45]  R. Burger,et al.  Intraperitoneal cisplatin and paclitaxel in ovarian cancer. , 2006, The New England journal of medicine.

[46]  Christopher P Crum,et al.  Human epididymis protein 4 (HE4) is a secreted glycoprotein that is overexpressed by serous and endometrioid ovarian carcinomas. , 2005, Cancer research.

[47]  K. Hatch,et al.  Validation of Referral Guidelines for Women With Pelvic Masses , 2005, Obstetrics and Gynecology.

[48]  D. Alberts,et al.  Role of pegylated liposomal doxorubicin in ovarian cancer. , 2005, Gynecologic oncology.

[49]  S. Rubin,et al.  Secondary surgical cytoreduction for advanced ovarian carcinoma. , 2004, The New England journal of medicine.

[50]  Steven Sun,et al.  Long-term survival advantage for women treated with pegylated liposomal doxorubicin compared with topotecan in a phase 3 randomized study of recurrent and refractory epithelial ovarian cancer. , 2004, Gynecologic oncology.

[51]  M. Markman,et al.  Expanded experience with an intradermal skin test to predict for the presence or absence of carboplatin hypersensitivity. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[52]  V. Torri,et al.  Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial , 2003, The Lancet.

[53]  P. Sabbatini,et al.  Analysis of patients with epithelial ovarian cancer or fallopian tube carcinoma retreated with cisplatin after the development of a carboplatin allergy. , 2002, Gynecologic oncology.

[54]  A. Gabizon.  Pegylated Liposomal Doxorubicin: Metamorphosis of an Old Drug into a New Form of Chemotherapy , 2001, Cancer investigation.

[55]  M. Buyse,et al.  The effect of debulking surgery after induction chemotherapy on the prognosis in advanced epithelial ovarian cancer. Gynecological Cancer Cooperative Group of the European Organization for Research and Treatment of Cancer. , 1995, The New England journal of medicine.